Merck Sharp & Dohme B.V.
USPTO PatentsView assignee record - 34 granted patents across 23 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Merck ranks #9,318 of 49,997 tracked US assignees by granted-patent volume, with 34 patents across 23 technology areas.
- #9,318
- of 49,997 US assignees by volume
- Top 38%
- by Innovation Score (39.4/100)
- 15.8
- avg claims per patent
- -64%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R9318 · Foreign Corporation #9,318 · 34 grants
GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL
- GRANTS-SMALL 34 grants
- UPPER-Q #9,318/49,997
- PHOTO-FINISH Lund
- CPC-FOCUS A61P · 23 areas
- INNOV-THIN 39.4/100
- CLAIMS-RICH 15.8 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-DROP -64% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Lund, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Merck’s 39.4 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Merck
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- D & D Group PTY · near
D & D Group PTY · near
39 score
- Rethink Robotics · near
Rethink Robotics · near
39 score
- Curis · near
Curis · near
39 score
- Hiperwall · near
Hiperwall · near
39 score
- Merck Sharp & Dohme… · this assignee
Merck Sharp & Dohme… · this assignee
39 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Merck's Innovation Score is 39.4/100 (top 38% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Merck?
Each dot is one of Merck’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Merck’s own 15.8 claims/patent is at or below the 17.8 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Merck's grants concentrate
Merck Sharp & Dohme B.V. is a focused PatentsView assignee: 23 CPC subclasses with 67.6% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (10 grants) versus a trough of 1 in 2024. By volume, Merck sits between Lund, Inc. and Mold-masters (2007) Limited.
Merck's three-year grant acceleration
Merck Sharp & Dohme B.V. shows 1 grants in 2022–2024 against only 10 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Merck's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Lund
Lund, Inc.
34 patents
- Lutonix
Lutonix, Inc.
34 patents
- Lytro
Lytro, Inc.
34 patents
- Magnacom
Magnacom Ltd.
34 patents
- Mianyang HKC Opto…
Mianyang HKC Optoelectronics Technology Co., Ltd
34 patents
- Mikuni Electron
Mikuni Electron Corporation
34 patents
- Mobiletron
Mobiletron Electronics Co., Ltd.
34 patents
- Mold-masters (200…
Mold-masters (2007) Limited
34 patents
- Merck Sharp & Doh… ◀
Merck Sharp & Dohme B.V.
34 patents
What this shows Merck holds 34 patents at rank #9,313, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Merck
By rank, the assignees closest to #9,313 in granted patent volume.
- Lund, Inc. #9,309 · 34 patents
- Lutonix, Inc. #9,310 · 34 patents
- Lytro, Inc. #9,311 · 34 patents
- Magnacom Ltd. #9,312 · 34 patents
- Mianyang HKC Optoelectronics Technology Co., Ltd #9,314 · 34 patents
- Mikuni Electron Corporation #9,315 · 34 patents
- Mobiletron Electronics Co., Ltd. #9,316 · 34 patents
- Mold-masters (2007) Limited #9,317 · 34 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Merck's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Assignees with similar portfolio profiles
Two PlainPatent-derived peer sets for Merck, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Merck ranks #848 of 6,058 assignees by patent count in that subclass.
Similar innovation score
Nearest assignees by Innovation Score (39 here).
Merck's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
39 Top 38% higher than 62% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 10 | 29.4% |
| 2016 | 2 | 5.9% |
| 2017 | 7 | 20.6% |
| 2018 | 4 | 11.8% |
| 2019 | 2 | 5.9% |
| 2020 | 2 | 5.9% |
| 2021 | 6 | 17.6% |
| 2024 | 1 | 2.9% |
Which technologies does Merck Sharp & Dohme B.V. patent most?
Top 15 of 23 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Merck Sharp & Dohme B.V.'s patent record in context - here's where to go next.
- Merck Sharp & Dohme B.V.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 67.6% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #9,318 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Merck Sharp & Dohme B.V. against Lund, Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 39.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.